The annual meeting of the American Society of Clinical Oncology (ASCO) is approaching, and Wall Street’s attention is fixed on a single experimental drug: ivonescimab, co-developed by Akeso and Summit Therapeutics.
Next month’s ASCO conference will feature a plenary session where survival data for ivonescimab in lung cancer treatment will be presented. This high-profile platform has intensified speculation about the drug’s efficacy and potential market impact.
For full access to the upcoming analysis and insights, STAT+ subscribers can sign up to receive the Biotech Scorecard newsletter directly in their inbox.
Related articles
Marty Makary's FDA Resignation Highlights Agency Turmoil Amid Leadership Shifts
On Tuesday, Food and Drug Administration Commissioner Marty Makary resigned from his position, leaving a vacancy at the top of the agency to match the...
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...